Pharmacological aspects of experimental headache models in relation to acute antimigraine therapy
- 1 June 1999
- journal article
- review article
- Published by Elsevier in European Journal of Pharmacology
- Vol. 375 (1-3) , 61-74
- https://doi.org/10.1016/s0014-2999(99)00197-1
Abstract
No abstract availableKeywords
This publication has 99 references indexed in Scilit:
- Vasoconstriction in human isolated middle meningeal arteries: determining the contribution of 5‐HT1B‐ and 5‐HT1F‐receptor activationBritish Journal of Clinical Pharmacology, 1999
- Selective, Orally Active 5-HT1D Receptor Agonists as Potential Antimigraine AgentsJournal of Medicinal Chemistry, 1997
- Characterization of LY344864 as a pharmacological tool to study 5-HT1F receptors: Binding affinities, brain penetration and activity in the neurogenic dural inflammation model of migraineLife Sciences, 1997
- PREVALENCE AND IMPACT OF MIGRAINENeurologic Clinics, 1997
- Ketanserin and ritanserin discriminate between recombinant human 5-HT1Dα and 5-HT1Dβ receptor subtypesEuropean Journal of Pharmacology: Molecular Pharmacology, 1995
- Expression of serotonin receptor mRNAs in blood vesselsFEBS Letters, 1995
- Evolution of a Novel Series of [(N,N-Dimethylamino)propyl]- and Piperazinylbenzanilides as the First Selective 5-HT1D AntagonistsJournal of Medicinal Chemistry, 1994
- Nitric oxide is a key molecule in migraine and other vascular headachesTrends in Pharmacological Sciences, 1994
- Migraine pain associated with middle cerebral artery dilatation: reversal by sumatriptanThe Lancet, 1991
- Proposals for the classification and nomenclature of functional receptors for 5-hydroxytryptamineNeuropharmacology, 1986